March 3, 2026Open Access

Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom

Key Points

The MVA-BN vaccine induces neutralizing antibodies for monkeypox virus clades Ib and IIb.
A higher immune response was observed for clade IIb compared to clade Ib.
This analysis highlights the potential for the vaccine to provide cross-neutralizing effects.
Such findings emphasize the importance of vaccination strategies against emerging viruses.

Abstract

A 2-dose regimen of the vaccine modified vaccinia Ankara-Bavarian Nordic (MVA-BN) can generate neutralizing antibodies for monkeypox virus clades Ib and IIb. We observed higher response to clade IIb; that result provides evidence that MVA-BN vaccination can induce cross-neutralizing antibodies for monkeypox virus clade Ib as well as for clade IIb.

Monkeypox Virus Antibodies in Healthy Persons after Vaccination with MVA-BN, United Kingdom

Key Points

Abstract

Cite This Study